Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have earned an average recommendation of “Hold” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.79.

MRNS has been the topic of a number of analyst reports. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a report on Monday, September 23rd.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the second quarter worth approximately $727,000. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth about $813,000. Hussman Strategic Advisors Inc. raised its stake in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $206,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $0.31 on Tuesday. The firm has a market capitalization of $17.10 million, a P/E ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a one year low of $0.26 and a one year high of $11.26. The company’s 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.29.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.